Torray Investment Partners’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-107,934
Closed -$3.23M 95
2024
Q1
$3.23M Buy
107,934
+733
+0.7% +$21.5K 0.48% 58
2023
Q4
$3.41M Buy
107,201
+2,685
+3% +$84.3K 0.55% 52
2023
Q3
$3.69M Sell
104,516
-4,276
-4% -$163K 0.65% 51
2023
Q2
$4.14M Sell
108,792
-2,015
-2% -$80.3K 0.72% 49
2023
Q1
$4.18M Sell
110,807
-17,757
-14% -$683K 0.75% 47
2022
Q4
$5.45M Sell
128,564
-2,866
-2% -$118K 0.98% 36
2022
Q3
$4.22M Sell
131,430
-278
-0.2% -$9.76K 0.84% 40
2022
Q2
$4.28M Sell
131,708
-1,464
-1% -$47.4K 0.82% 43
2022
Q1
$4.82M Sell
133,172
-6,218
-4% -$213K 0.77% 50
2021
Q4
$5.51M Sell
139,390
-6,308
-4% -$263K 0.81% 50
2021
Q3
$6.37M Sell
145,698
-1,076
-0.7% -$48.3K 0.97% 41
2021
Q2
$5.99M Buy
146,774
+513
+0.4% +$19.8K 0.88% 43
2021
Q1
$4.8M Buy
146,261
+1,063
+0.7% +$40K 0.75% 46
2020
Q4
$5.9M Sell
145,198
-6,266
-4% -$234K 0.97% 38
2020
Q3
$5.54M Sell
151,464
-5,176
-3% -$187K 1.02% 38
2020
Q2
$5.31M Sell
156,640
-22,786
-13% -$621K 1% 39
2020
Q1
$3.8M Buy
179,426
+19,507
+12% +$435K 0.84% 43
2019
Q4
$3.57M Sell
159,919
-539,421
-77% -$11.8M 0.61% 49
2019
Q3
$14.2M Buy
+699,340
New +$13.8M 1.54% 34

Other funds holding GMAB

Torray Investment Partners's GMAB Position: Q2 2024 in Review

Torray Investment Partners sold out of Genmab (GMAB) in Q2 2024, closing a stake of 107,934 shares — an estimated $3.23M sold.

Torray Investment Partners first reported a position in GMAB in Q3 2019 and held it in 19 quarters. The position peaked at $14.2M in Q3 2019. 219 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

  • Torray Investment Partners reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
  • Torray Investment Partners sold 107,934 Genmab shares in Q2 2024, an estimated $3.23M.
  • Torray Investment Partners first reported a position in Genmab in Q3 2019 and held it in 19 quarters.
  • Torray Investment Partners's Genmab position peaked at $14.2M in Q3 2019.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on Torray Investment Partners's 13F filing for Q2 2024, filed 6 Aug 2024.